LEI:
549300Q7EXQQH6KF7Z84
5 June 2024
RTW Biotech Opportunities
Ltd
(the "Company")
Transaction in Own
Shares
The Company announces that on 4 June
2024 it bought back 200,000 of its own shares, to be held as
treasury shares, at an average price $1.42 per share.
Further details are set out
below:
Number of shares held as treasury
shares following this purchase: 10,253,791.
Total shares in issue excluding
treasury shares following this purchase: 335,713,649.
The Company has bought back these
shares under the authority granted by shareholders at its Annual
General Meeting in May 2024, which permits the Company to
repurchase a maximum of 14.99% of its ordinary shares. The actual
number of shares repurchased by the Company will depend on market
conditions. This authority lasts until the next shareholder
authority granted (expected to be at the Annual General Meeting in
2025), or until expressly revoked by shareholders.
The above figure of 335,713,649 may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules.
No maximum consideration payable has
been determined by the Company, but the Company is unable to pay a
price for any shares pursuant to the buyback which would equate to
a premium to the net asset value. It is the Company's current
intention to hold any shares bought back in treasury.
The Company has instructed Numis
Securities Limited as its broker in respect of its buyback
transactions. This arrangement is in accordance with the UKLA
Listing Rules and the Company's general authority to repurchase
shares.
For
Further Information:
|
RTW
Investments, LP
|
+44
(0)20 7959 6361
biotechopportunities@rtwfunds.com
|
|
Woody Stileman, Managing
Director
Krisha McCune, Director, Investor
Relations
|
|
|
|
|
About
RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.